WallStreetZenWallStreetZen

NASDAQ: ABCL
Abcellera Biologics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ABCL

Based on 7 analysts offering 12 month price targets for Abcellera Biologics Inc

Min Forecast
$9.00-23.73%
Avg Forecast
$15.71+33.17%
Max Forecast
$30.00+154.24%

Should I buy or sell ABCL stock?

Based on 7 analysts offering ratings for Abcellera Biologics Inc.

Strong Buy
Strong Buy
6 analysts 85.71%
Buy
0 analysts 0%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ABCL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ABCL as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their ABCL stock forecasts and price targets.

ABCL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-12
lockedlocked$00.00+00.00%2026-09-29
lockedlocked$00.00+00.00%2026-09-24
lockedlocked$00.00+00.00%2026-08-11
lockedlocked$00.00+00.00%2026-08-06
Cantor Fitzgerald
Top 29%
72
Strong BuyMaintains$12.00+1.69%2026-08-06
Benchmark
Top 17%
84
Strong BuyUpgrades$11.00-6.78%2026-07-07

1 of 1

Forecast return on equity

Is ABCL forecast to generate an efficient return?

Company
-26.76%
Industry
25.06%
Market
177.77%
ABCL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ABCL forecast to generate an efficient return on assets?

Company
-18.34%
Industry
23.99%
ABCL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ABCL earnings per share forecast

What is ABCL's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$0.68
Avg 2 year Forecast
-$0.77
Avg 3 year Forecast
-$0.87

ABCL revenue forecast

What is ABCL's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$26.9M-59.4%
Avg 2 year Forecast
$31.3M-52.68%
Avg 3 year Forecast
$32.2M-51.33%
ABCL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ABCL revenue growth forecast

How is ABCL forecast to perform vs Biotechnology companies and vs the US market?

Company
-20.77%
Industry
30.45%
Market
14.13%
ABCL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ABCL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ABCL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABCL$11.80$15.71+33.17%Strong Buy
ARQT$28.82$41.00+42.26%Strong Buy
TLX$10.69$21.33+99.56%Strong Buy
LEGN$18.48$45.38+145.54%Buy
RLAY$16.28$26.70+64.00%Strong Buy
View Top Biotech Stocks

Abcellera Biologics Stock Forecast FAQ

Is Abcellera Biologics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: ABCL) stock is to Strong Buy ABCL stock.

Out of 7 analysts, 6 (85.71%) are recommending ABCL as a Strong Buy, 0 (0%) are recommending ABCL as a Buy, 1 (14.29%) are recommending ABCL as a Hold, 0 (0%) are recommending ABCL as a Sell, and 0 (0%) are recommending ABCL as a Strong Sell.

If you're new to stock investing, here's how to buy Abcellera Biologics stock.

What is ABCL's earnings growth forecast for 2026-2028?

(NASDAQ: ABCL) Abcellera Biologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.

Abcellera Biologics's earnings in 2026 is -$164,656,000.On average, 13 Wall Street analysts forecast ABCL's earnings for 2026 to be -$209,844,887, with the lowest ABCL earnings forecast at -$219,349,843, and the highest ABCL earnings forecast at -$199,604,064. On average, 12 Wall Street analysts forecast ABCL's earnings for 2027 to be -$236,305,457, with the lowest ABCL earnings forecast at -$288,460,067, and the highest ABCL earnings forecast at -$180,287,542.

In 2028, ABCL is forecast to generate -$267,181,231 in earnings, with the lowest earnings forecast at -$282,450,482 and the highest earnings forecast at -$206,042,905.

What is ABCL's revenue growth forecast for 2026-2028?

(NASDAQ: ABCL) Abcellera Biologics's forecast annual revenue growth rate of -20.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.

Abcellera Biologics's revenue in 2026 is $66,173,000.On average, 13 Wall Street analysts forecast ABCL's revenue for 2026 to be $8,237,730,257, with the lowest ABCL revenue forecast at $5,408,626,260, and the highest ABCL revenue forecast at $14,025,328,289. On average, 12 Wall Street analysts forecast ABCL's revenue for 2027 to be $9,601,538,058, with the lowest ABCL revenue forecast at $3,004,792,367, and the highest ABCL revenue forecast at $20,250,154,272.

In 2028, ABCL is forecast to generate $9,875,648,708 in revenue, with the lowest revenue forecast at $3,004,792,367 and the highest revenue forecast at $21,215,980,390.

What is ABCL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ABCL) forecast ROA is -18.34%, which is lower than the forecast US Biotechnology industry average of 23.99%.

What is ABCL's Price Target?

According to 7 Wall Street analysts that have issued a 1 year ABCL price target, the average ABCL price target is $15.71, with the highest ABCL stock price forecast at $30.00 and the lowest ABCL stock price forecast at $9.00.

On average, Wall Street analysts predict that Abcellera Biologics's share price could reach $15.71 by Oct 12, 2027. The average Abcellera Biologics stock price prediction forecasts a potential upside of 33.17% from the current ABCL share price of $11.80.

What is ABCL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ABCL) Abcellera Biologics's current Earnings Per Share (EPS) is -$0.54. On average, analysts forecast that ABCL's EPS will be -$0.68 for 2026, with the lowest EPS forecast at -$0.72, and the highest EPS forecast at -$0.65. On average, analysts forecast that ABCL's EPS will be -$0.77 for 2027, with the lowest EPS forecast at -$0.94, and the highest EPS forecast at -$0.59. In 2028, ABCL's EPS is forecast to hit -$0.87 (min: -$0.92, max: -$0.67).

What is ABCL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ABCL) forecast ROE is -26.76%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.